Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 12/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 2/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14629615 | 0.83 | CYP3A4 (0.41) | HPRT1CCNE1CDK2CYP3A4FAP | |
| SCHEMBL13360612 | 0.82 | CYP3A4 (0.56) | CYP3A4FAP | |
| SCHEMBL13360654 | 0.78 | HSP90AB1 (0.44) | CCNE1CDK2CYP3A4HSP90AA1HSP90AB1 | |
| SCHEMBL9177023 | 0.75 | CYP3A4 (0.49) | CYP3A4FAPHSP90AA1HSP90AB1 | |
| SCHEMBL9176435 | 0.75 | CYP3A4 (0.49) | CYP3A4FAPHSP90AA1HSP90AB1 | |
| SCHEMBL7263249 | 0.75 | CYP3A4 (0.49) | CYP3A4FAPHSP90AA1HSP90AB1 | |
| SCHEMBL13328656 | 0.74 | HSP90AA1 (0.33) | HPRT1CCNE1CDK2CYP3A4SLC29A1 | |
| SCHEMBL9171347 | 0.71 | HPRT1 (0.41) | HPRT1CDK2CYP3A4 | |
| SCHEMBL9175112 | 0.71 | HPRT1 (0.41) | HPRT1CDK2CYP3A4 | |
| SCHEMBL8752233 | 0.71 | HSP90AB1 (0.43) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723319-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2010-05-25 | — | — | US | disclosed |
| US-20100004440-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2010-01-07 | — | — | US | disclosed |
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004440-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | HPRT1 34/4885CCNE1 1216/4885CDK2 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.